RxDoctor Payments Data

Adrian Perez Cochran, MD

Cardiovascular Disease · Ponce, PRNPI 1215912308

Payments from drug & device makers

$6,326in general payments, 2019–2025

Across 152 payments — averaging $41.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$718
  • Medtronic$662
  • Boston Scientific$420
  • AstraZeneca$382
  • E.r. Squibb & Sons, L.L.C.$222
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$2,08033%
  • Travel & lodging$1993%
  • Food & beverage$3,85561%
  • Education$1923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson23$2,859
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)36$718
Medtronic(2 entities)10$662
Boston Scientific16$420
AstraZeneca18$382
E.r. Squibb & Sons, L.L.C.11$222
Boehringer Ingelheim9$219
Amgen9$181
PBG Puerto Rico LLC9$175
Johnson And Johnson International1$120
Merck1$91
Edwards Lifesciences2$79
Pfizer1$73
Eli Lilly Export S.A. Puerto Rico Branch2$44
Abbott1$27
Biotronik Inc.1$24
Pfizer Pharmaceuticals LLC1$17
Cordis US CORP.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,326 in reported general payments places this provider in the 70th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$19,449
Medicare patients
59
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban270$310,797
FarxigaDapagliflozin Propanediol231$219,939
Xigduo XrDapaglifloz Propaned/Metformin207$194,885
BrilintaTicagrelor110$97,357
JardianceEmpagliflozin76$83,432
Trijardy XrEmpaglifloz/Linaglip/Metformin64$74,294
EntrestoSacubitril/Valsartan58$66,179
Synjardy XrEmpagliflozin/Metformin Hcl45$56,684
XareltoRivaroxaban47$50,170
Repatha SureclickEvolocumab50$40,168
SynthroidLevothyroxine Sodium350$40,030
JanumetSitagliptin Phos/Metformin Hcl24$33,622
JanuviaSitagliptin Phosphate21$28,162
Repatha PushtronexEvolocumab38$26,841
Fenofibric AcidFenofibric Acid (Choline)284$24,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$382$317,297341 claims
PfizerEliquis$73$310,797270 claims
Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Tradjenta, Synjardy$219$274,805233 claims
MerckJanumet, Januvia, Janumet Xr$91$77,58659 claims
Johnson & JohnsonXarelto$2,859$50,17047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →